LEXINGTON, Mass. (AP) — Biotechnology company AMAG Pharmaceuticals Inc. said Tuesday that regulators have accepted newly submitted data on its anemia drug candidate Feraheme. The drugmaker said the FDA plans to make a ruling on Feraheme by June 29. AMAG asked the agency to approve the drug for sale in December 2007, but the agency asked for more information in October and again in December. Feraheme, or ferumoxytol, is an injection intended to treat iron deficiency anemia in patients with chronic kidney disease.